Xencor stock falls 3.52 percent as Truist lifts its target

Published on 09/29/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xencor stock stood at EUR 21.90 at Lang & Schwarz on September 29, 2026, down 3.52 percent from EUR 22.70 on September 28, 2026. Truist set a USD 29.00 target.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor stock (ISIN US98401F1057) was trading at EUR 21.90 at Lang & Schwarz on September 29, 2026 at 5:40 p.m. CEST, down 3.52 percent versus the prior close of EUR 22.70 on September 28, 2026. The move came as Truist reiterated its Buy rating and raised its price target from USD 27.00 to USD 29.00, according to MarketBeat on September 28, 2026.

Truist target reaches USD 29.00

The new target gives the clinical-stage biotechnology company a higher valuation hurdle while keeping the rating constructive. The same MarketBeat report cited a Moderate Buy consensus and an average price target of USD 31.38, with individual targets reaching USD 46.00.

The valuation picture is mixed rather than purely earnings-led. Xencor had a market capitalization of USD 1.8 billion as of September 29, 2026, while its 52-week range stood at USD 10.38 to USD 30.61.

Q2 revenue climbs 17.40 percent

Xencor's latest reported quarter delivered USD 51.22 million in revenue, up 17.40 percent from the prior-year quarter. Adjusted EPS was a loss of USD 0.29, compared with the USD 0.80 loss expected by analysts, a USD 0.51 improvement versus consensus, according to MarketBeat. The results were reported for the quarter ended June 30, 2026, and released on August 5, 2026.

The comparison matters because revenue growth and a narrower adjusted loss support the analyst case even though Xencor remains loss-making. The company is developing engineered antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious conditions.

Stock trades below its yearly high

The USD 30.61 52-week high remains above the September 29 market capitalization snapshot, leaving pipeline progress and future licensing income as important valuation variables. Xencor's investor page listed a September 2, 2026 presentation at the Cantor Global Healthcare Conference, according to Xencor.

After the Xetra close

After the Xetra close, Xencor stock was trading at EUR 21.90 at Lang & Schwarz on September 29, 2026 at 5:40 p.m. CEST, down 3.52 percent versus the Lang & Schwarz prior close of EUR 22.70 on September 28, 2026.